Article
Oncogene aberrations drive medulloblastoma progression, not initiation
7 May 2025
Abstract excerpt
Abstract Despite recent advances in understanding disease biology, treatment of group 3/4 medulloblastoma remains a therapeutic challenge in paediatric neuro-oncology 1 . Bulk-omics approaches have identified considerable intertumoural heterogeneity in group 3/4 medulloblastoma, including the presence of clear single-gene oncogenic drivers in only a subset of cases, whereas in most cases, large-scale copy number...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
